Oncolin Therapeutics, Inc. Appoints Member of National Cancer Institute Advisory Board to its Scientific Advisory Board
HOUSTON--(BUSINESS WIRE)--Oncolin Therapeutics, Inc., (OTCBB:OCOL - News) is very pleased to announce that Dr. Daniel Von Hoff has joined the company’s Scientific Advisory Board (SAB). Dr. Von Hoff is generally considered to be one of the world’s leading experts in oncology drug development and is an advisor in some capacity to a large number of oncology companies.